Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of “Buy” from Analysts
Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM – Get Free Report) have been given a consensus recommendation of “Buy” by the six analysts that are presently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year […]
Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM – Get Free Report) have been given a consensus recommendation of “Buy” by the six analysts that are presently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year […]
